Biotech Investors & VC Firms in Stockholm
16 firms in this list, with a median first check of $1.1M. 5 of them lead rounds. Generated from verified public data and updated continuously.
HealthCap
StockholmSeed–Growth
33 people
Industrifonden
StockholmPre-Seed–Series A$960K – $4.8M
34 people
Procuritas
StockholmGrowth
32 people
Kinnevik
StockholmSeed–Growth
20 people
Nordic Capital
StockholmGrowth–Late Stage
13 people
Sciety
StockholmSeed–Growth
21 people
EIR Ventures
StockholmSeed–Series A
10 people
Navigare Ventures
StockholmSeed–Growth
6 people
Curitas Ventures
StockholmSeed–Growth
5 people
Trellis Road I Fund AB
StockholmPre-Seed–Seed
2 people
Sommet AB
StockholmSeed–Series A
1 person
MedCap AB
StockholmSeed–Series A
3 people
Leksell Social Ventures
StockholmPre-Seed–Seed$1M
2 people
First Venture
StockholmSeed–Growth
1 person
SEB Greentech Venture Capital
StockholmSeed–Growth$1.1M – $4.3M
4 people
EQT Life Sciences
AmsterdamSeed–Late Stage$11M – $66M
59 people
Frequently asked questions
- Who are the top biotech investors & vc firms in stockholm?
- Top biotech investors & vc firms in stockholm include HealthCap, Industrifonden, Procuritas, Kinnevik, Nordic Capital, Sciety, EIR Ventures, Navigare Ventures — 16 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in stockholm?
- The median first check among the 16 biotech investors & vc firms in stockholm tracked here is $1.1M.
- How many biotech investors & vc firms in stockholm lead rounds?
- 5 of the 16 biotech investors & vc firms in stockholm tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (12929)Investors & VC Firms in United States (11967)Investors & VC Firms in Europe (5859)Investors & VC Firms in Global (4787)AI & Machine Learning Investors & VC Firms (4629)Fintech Investors & VC Firms (4588)SaaS Investors & VC Firms (4239)Healthtech Investors & VC Firms (4227)Enterprise Software Investors & VC Firms (4136)Crypto & Web3 Investors & VC Firms (3986)
Data sourced from public filings and firms' own websites — see our methodology.


















































